Effects of Social Media Use on Young Adults' E-Cigarette Use
Launched by UNIVERSITY OF OKLAHOMA · Nov 15, 2023
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how using social media affects e-cigarette use among young adults. Researchers want to find out if cutting back on social media can help young adults reduce their vaping habits and improve their mental health. Participants will complete surveys and share screenshots of their social media use to help the researchers understand these effects better.
To join the study, you need to be between 18 and 25 years old, use social media daily, own a smartphone, and have vaped at least a few times in the past month. If you meet these criteria and live in the United States, you might be eligible to participate. Throughout the trial, you'll be compared to others who continue using social media as usual, so the researchers can see if less time online really makes a difference in e-cigarette use.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18-25
- • Daily social media use
- • Ownership of a smartphone
- • Vaping (i.e., use of a nicotine e-cigarette) on 1-19 days of the past 30 days
- • Residing in the United States
- Exclusion Criteria:
- • -Lack of capacity to provide informed consent
About University Of Oklahoma
The University of Oklahoma, a leading research institution, is dedicated to advancing healthcare through innovative clinical trials and research initiatives. With a robust network of interdisciplinary experts and state-of-the-art facilities, the university fosters an environment that promotes scientific discovery and the development of new treatments. Its commitment to patient-centered research ensures that clinical trials not only adhere to the highest ethical standards but also aim to address pressing health challenges. By collaborating with various stakeholders, including industry partners and healthcare providers, the University of Oklahoma seeks to translate research findings into tangible benefits for communities, ultimately enhancing the quality of care and improving health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oklahoma City, Oklahoma, United States
Patients applied
Trial Officials
Erin A Vogel, PhD
Principal Investigator
University of Oklahoma
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported